Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-HAE: ADX-324 in Hereditary Angioedema
NCT06960213Phase 3Recruiting
- Sponsor
- ADARx Pharmaceuticals
- Start
- Aug 2025
- Primary completion
- Nov 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 24
01
Overview
A Phase 3 trial of onvuzosiran in hereditary angioedema (HAE), sponsored by ADARx Pharmaceuticals. Started Aug 2025; status: recruiting.
02
Drugs
onvuzosiran
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT06960213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06960213.